Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression

Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression

The v-raf murine sarcoma viral oncogenic homolog B1 (BRAF) V600E is a rare mutation that functions as an oncogenic driver in patients with non-small cell lung cancer (NSCLC) leading to the overactivation of the RAS-RAF-MEK-ERK (MAPK) pathway and the subsequent uncontrolled cell proliferation. Unders...

Full description

Bibliographic Details
Main Authors: Huimin Zhang, Xiaofeng Cong, Jiaxin Yin, Chen Chen, Ziling Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
dabrafenib
trametinib
BRAF V600E mutation
BRCA2 germline mutation
lung adenocarcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1387388/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1387388/full

Similar Items